1513 related articles for article (PubMed ID: 15531005)
21. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Gaciong Z; Placha G
J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management.
Sircar AR; Kumar A; Lal M
J Assoc Physicians India; 2001 Sep; 49():885-8. PubMed ID: 11837755
[TBL] [Abstract][Full Text] [Related]
24. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
[TBL] [Abstract][Full Text] [Related]
25. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
[TBL] [Abstract][Full Text] [Related]
26. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
27. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
29. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
[TBL] [Abstract][Full Text] [Related]
30. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
31. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization.
Porter JA; Raebel MA; Conner DA; Lanty FA; Vogel EA; Gay EC; Merenich JA
Am J Manag Care; 2004 Jun; 10(6):369-76. PubMed ID: 15209480
[TBL] [Abstract][Full Text] [Related]
32. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
[TBL] [Abstract][Full Text] [Related]
33. Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study.
Stimac D; Ruzić A; Majanović SK
Coll Antropol; 2004 Jun; 28(1):215-21. PubMed ID: 15636078
[TBL] [Abstract][Full Text] [Related]
34. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
[TBL] [Abstract][Full Text] [Related]
35. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
36. Influence of weight reduction by sibutramine on female sexual function.
Kim KK; Kang HC; Kim SS; Youn BB
Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
[TBL] [Abstract][Full Text] [Related]
37. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
[TBL] [Abstract][Full Text] [Related]
38. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Caterson ID; Finer N; Coutinho W; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Legler UF; Shepherd GM; Rode RA; Perdok RJ; Renz CL; James WP;
Diabetes Obes Metab; 2012 Jun; 14(6):523-30. PubMed ID: 22192338
[TBL] [Abstract][Full Text] [Related]
39. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
40. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C; Weeke P; Fosbøl EL; Brendorp B; Køber L; Coutinho W; Sharma AM; Van Gaal L; Finer N; James WP; Caterson ID; Rode RA; Torp-Pedersen C; ;
Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
